Coronavirus Update: AbbVie Jumps Into Antiviral Research With Scripps Pact

 
• By Scrip Team
  
Generate a summary of this article
Listen to this article
Beta

AbbVie is taking the plunge into the highly competitive area of antiviral research through a new alliance, while Pfizer files for US approval of an additional mRNA booster shot and a vaccines group is unhappy about planned IP waivers. 

WTO HQ
proposed WTO TRIPS vaccine waivers seen as insufficient by vaccine alliance • Source: Alamy

AbbVie Inc. is teaming up with non-profit Scripps Research to develop direct-acting anti-viral treatments for COVID-19. While drug development during the pandemic has focused mainly on vaccines, emerging antiviral treatments are gaining ground so AbbVie and Scripps must contend with the likes of Pfizer Inc.'s Paxlovid (nirmatrelvir/ ritonavir), Merck & Co., Inc.'s Lagevrio (molnupiravir) and Gilead Sciences, Inc.'s Veklury (remdesivir) which are already available.

Paxlovid is expected to make $22bn this year, while Merck anticipates $5bn to $6bn in Lagevrio sales in the same...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains